Developer of novel immuno-oncology and immune-therapies intended for the treatment of haematologic malignancies and auto-immune diseases. The company's mmuno-oncology and immune-therapies enables blood cancers patient to have extended survival time from the disease.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Accelerator/Incubator | Completed | Startup |
Name | Representing | Role | Since |
---|---|---|---|
Alan Liddle | HaemaLogiX | Board Member | 000 0000 |
Bryce Carmine | HaemaLogiX | Chief Executive Officer & Chairman | 000 0000 |
John Cullity | HaemaLogiX | Board Member | 000 0000 |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Cicada Innovations | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |